Trial · NCT01125774
Results by group18
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 18 of 18
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Clinical Adverse Events (AEs) | Telcagepant 140 mg | 1582 | 0.19 | Participants | |
| Number of Participants With Clinical Adverse Events (AEs) | Placebo | 804 | 0.26 | Participants | |
| Number of Participants Who Discontinued Study Due to a Clinical AE | Telcagepant 140 mg | 66 | 0.19 | Participants | |
| Number of Participants Who Discontinued Study Due to a Clinical AE | Placebo | 36 | 0.26 | Participants | |
| Number of Participants With Laboratory AEs | Telcagepant 140 mg | 76 | 0.19 | Participants | |
| Number of Participants With Laboratory AEs | Placebo | 30 | 0.26 | Participants | |
| Number of Participants Who Discontinued Study Due to a Laboratory AE | Telcagepant 140 mg | 8 | 0.19 | Participants | |
| Number of Participants Who Discontinued Study Due to a Laboratory AE | Placebo | 2 | 0.26 | Participants | |
Mean Monthly Headache Days During Entire Study Period Among Participants With Menstrually-related Migraine (MRM) or Pure Menstrual Migraine (PMM) Who Have an Average of 5 or More Moderate or Severe Migraine Headaches Per Month at Baseline | Telcagepant 140 mg | 8.8 | Standard Error 0.19 | Days per month | |
Mean Monthly Headache Days During Entire Study Period Among Participants With Menstrually-related Migraine (MRM) or Pure Menstrual Migraine (PMM) Who Have an Average of 5 or More Moderate or Severe Migraine Headaches Per Month at Baseline | Placebo | 9.3 | Standard Error 0.26 | Days per month | |
| Mean Monthly Headache Days During Entire Study Period Among Participants With MRM Who Have an Average of 5 or More Moderate or Severe Migraine Headaches Per Month at Baseline | Telcagepant 140 mg | 9.3 | Standard Error 0.20 | Days per month | |
| Mean Monthly Headache Days During Entire Study Period Among Participants With MRM Who Have an Average of 5 or More Moderate or Severe Migraine Headaches Per Month at Baseline | Placebo | 9.6 | Standard Error 0.28 | Days per month | |
| Mean Monthly On-drug Headache Days During the Entire Study Period Among Participants With MRM or PMM Who Have an Average of 5 or More Moderate or Severe Migraine Headaches Per Month at Baseline | Telcagepant 140 mg | 2.5 | Standard Error 0.05 | Days per month | |
| Mean Monthly On-drug Headache Days During the Entire Study Period Among Participants With MRM or PMM Who Have an Average of 5 or More Moderate or Severe Migraine Headaches Per Month at Baseline | Placebo | 2.9 | Standard Error 0.08 | Days per month | |
| Mean Monthly On-drug Headache Days During the Entire Study Period Among Participants With MRM Who Have an Average of 5 or More Moderate or Severe Migraine Headaches Per Month at Baseline | Telcagepant 140 mg | 2.6 | Standard Error 0.06 | Days per month | |
| Mean Monthly On-drug Headache Days During the Entire Study Period Among Participants With MRM Who Have an Average of 5 or More Moderate or Severe Migraine Headaches Per Month at Baseline | Placebo | 3.0 | Standard Error 0.08 | Days per month | |
| Mean Monthly On-drug Headache Days During the Entire Study Period Among Participants With PMM Who Have an Average of 3 or More Moderate or Severe Migraine Headaches Per Month at Baseline | Telcagepant 140 mg | 2.1 | Standard Error 0.08 | Days per month | |
| Mean Monthly On-drug Headache Days During the Entire Study Period Among Participants With PMM Who Have an Average of 3 or More Moderate or Severe Migraine Headaches Per Month at Baseline | Placebo | 2.2 | Standard Error 0.12 | Days per month |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01125774/results